Abstract
A series of 32 L-serinyl hydrazone derivatives have been synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, being also evaluated their cell viabilities in non infected and infected macrophages with Mycobacterium bovis Bacillus Calmette-Guerin (BCG). The compounds 8c, 8e, 8h and 8i, were non-cytotoxic and exhibited an important minimum inhibitory concentration (MIC) activity between 25 and 100μg/mL, which can be compared with that of the tuberculostatic drug D-cicloserine (5-20μg/mL).
Keywords: BCG, D-cycloserine, hydrazone, L-cycloserine, L-serine, Mycobacterium, tuberculosis, L-serinyl hydrazone, tuberculostatic drug D-cicloserine, isoniazid and rifampin
Medicinal Chemistry
Title: Synthesis and Antitubercular Activity of New L-serinyl Hydrazone Derivatives
Volume: 7 Issue: 6
Author(s): Alessandra Campbell Pinheiro, Carlos Roland Kaiser, Thais Cristina Mendonca Nogueira, Samir Aquino Carvalho, Edson Ferreira da Silva, Larisse de Oliveira Feitosa, Maria das Gracas Muller de Oliveira Henriques, Andre Luis Peixoto Candea, Maria Cristina Silva Lourenco and Marcus Vinicius Nora de Souza
Affiliation:
Keywords: BCG, D-cycloserine, hydrazone, L-cycloserine, L-serine, Mycobacterium, tuberculosis, L-serinyl hydrazone, tuberculostatic drug D-cicloserine, isoniazid and rifampin
Abstract: A series of 32 L-serinyl hydrazone derivatives have been synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv, being also evaluated their cell viabilities in non infected and infected macrophages with Mycobacterium bovis Bacillus Calmette-Guerin (BCG). The compounds 8c, 8e, 8h and 8i, were non-cytotoxic and exhibited an important minimum inhibitory concentration (MIC) activity between 25 and 100μg/mL, which can be compared with that of the tuberculostatic drug D-cicloserine (5-20μg/mL).
Export Options
About this article
Cite this article as:
Campbell Pinheiro Alessandra, Roland Kaiser Carlos, Cristina Mendonca Nogueira Thais, Aquino Carvalho Samir, Ferreira da Silva Edson, de Oliveira Feitosa Larisse, das Gracas Muller de Oliveira Henriques Maria, Luis Peixoto Candea Andre, Cristina Silva Lourenco Maria and Vinicius Nora de Souza Marcus, Synthesis and Antitubercular Activity of New L-serinyl Hydrazone Derivatives, Medicinal Chemistry 2011; 7 (6) . https://dx.doi.org/10.2174/157340611797928325
DOI https://dx.doi.org/10.2174/157340611797928325 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders
Current Medicinal Chemistry Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Current Pharmaceutical Design Purine Salvage Pathway in Mycobacterium tuberculosis
Current Medicinal Chemistry New Insights into the Immune Response to Pneumococci
Current Respiratory Medicine Reviews β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases
Current Topics in Medicinal Chemistry Recent Development and Future Perspective of Antitubercular Therapy
Anti-Infective Agents in Medicinal Chemistry Current Bioactive Azole-Containing Natural Products
Current Bioactive Compounds Molecular Interactions in Interleukin and Toll-like Receptor Signaling Pathways
Current Pharmaceutical Design Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Current Medicinal Chemistry QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
Current Pharmaceutical Design Epigenetic Control Using Natural Products and Synthetic Molecules
Current Medicinal Chemistry New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry